Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Chubb
Queensland Health
QuintilesIMS
Boehringer Ingelheim
Dow
Merck
McKinsey

Generated: July 23, 2018

DrugPatentWatch Database Preview

Levocetirizine dihydrochloride - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for levocetirizine dihydrochloride and what is the scope of levocetirizine dihydrochloride freedom to operate?

Levocetirizine dihydrochloride
is the generic ingredient in three branded drugs marketed by Apotex Inc, L Perrigo Co, Lannett Co Inc, Taro Pharm Inds Ltd, Sanofi-aventis Us, Allied Pharma Inc, Dr Reddys Labs Ltd, Fosun Pharma, Glenmark Generics, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Micro Labs Ltd India, Sciegen Pharms Inc, Sun Pharm Inds Ltd, Sun Pharma Global, Synthon Pharms, and Teva Pharms, and is included in twenty-two NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Levocetirizine dihydrochloride has thirty patent family members in twenty-four countries.

There are thirteen drug master file entries for levocetirizine dihydrochloride. Thirty-six suppliers are listed for this compound.
Pharmacology for levocetirizine dihydrochloride
Synonyms for levocetirizine dihydrochloride
(-)-Cetirizine dihydrochloride; 2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid dihydrochloride
(2-(4-((R)-(4-Chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
(R)-Cetirizine dihydrochloride
[2-[4-[(R)-(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid 2HCl
[2-[4-[(R)-(4-CHLOROPHENYL)PHENYLMETHYL]-1-PIPERAZINYL]ETHOXY]-ACETIC ACID DIHYDROCHLORIDE
018L870
130018-87-0
2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]ethanoic acid dihydrochloride
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid;dihydrochloride
2-[2-[4-[(R)-(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride
A806003
AC-549
Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride
AK176131
AKOS015994681
API0000012
API0003160
AT-15143
BC204366
BG0136
CHEMBL1201190
CTK8F2040
D08118
FT-0631130
KS-00000XIF
KS-1177
L0264
Levoceitrizine dihydrochloride
Levocetirizine 2HCl
Levocetirizine dihydrochloride (USAN)
Levocetirizine dihydrochloride [USAN]
Levocetirizine dihydrochloride, >=98% (HPLC)
Levocetirizine HCl
Levocetirizine hydrochloride (JAN)
LS-186529
MFCD07366507
MolPort-003-983-419
PGLIUCLTXOYQMV-GHVWMZMZSA-N
SCHEMBL144375
SOD6A38AGA
UCB 28556
UCB-28556
UNII-64O047KTOA component PGLIUCLTXOYQMV-GHVWMZMZSA-N
UNII-SOD6A38AGA
Xusal
Xyzal (TN)
Xyzal Allergy 24hr
Xyzall

US Patents and Regulatory Information for levocetirizine dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hetero Labs Ltd Iii LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 091264-001 Jun 29, 2012 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Synthon Pharms LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 090229-001 Nov 26, 2010 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allied Pharma Inc LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 204323-001 Dec 20, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride SOLUTION;ORAL 022157-001 Jan 28, 2008 AA RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for levocetirizine dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride SOLUTION;ORAL 022157-001 Jan 28, 2008 ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 ➤ Sign Up ➤ Sign Up
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for levocetirizine dihydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00085 Netherlands ➤ Sign Up PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
01C/045 Belgium ➤ Sign Up PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
McKinsey
Colorcon
Boehringer Ingelheim
Harvard Business School
Cerilliant
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.